RxDoctor Payments Data

Johann Othmer

Psychiatry · Lancaster, PANPI 1518050327

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $4,550 of the $7,297 with a category attached, or 62.4%. AbbVie accounts for 76.2% of it on its own, with 15 other manufacturers making up the rest. 2023 is the largest year on record at $4,756, 8.9 times the $535 reported in 2019. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,297in general payments, 2019–2025

Across 140 payments — averaging $52.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Takeda Pharmaceuticals U.S.A., Inc.$319
  • Ironshore Pharmaceuticals Inc.$256
  • Alkermes, Inc.$250
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$230
  • Supernus Pharmaceuticals, Inc.$180
  • plus $499 from 10 others

What the payments were for

  • Speaking & faculty fees$4,55062%
  • Food & beverage$2,51334%
  • Education$2343%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,297 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania →

Other psychiatry in Lancaster

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →